If you have been reading about system suitability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Method validation examines whether an HPLC procedure is suitable for its intended purpose. Common parameters include accuracy, precision, specificity, linearity, range, detection limit, quantification limit, and robustness. Accuracy describes closeness to a true or accepted value, while precision describes agreement among repeated measurements. Specificity shows whether the method can measure the analyte without interference from related substances. Robustness tests small deliberate changes in flow, temperature, or solvent composition. Validation is not a one-time event; methods may need partial revalidation after changes to instruments, columns, sample handling, or specification limits. Regulatory guidance provides frameworks, but some details remain method-specific.
Regulatory and pharmacopeial texts shape how HPLC testing is performed and documented. The International Council for Harmonisation provides validation guidance, while pharmacopeias publish general chromatography chapters and monographs for specific materials. Accreditation standards such as ISO/IEC 17025 address laboratory competence and traceability. Inspectors may review instrument qualification, analyst training, reference material control, and electronic records. Open questions include how best to validate methods for new complex products and how to handle automated data processing. Laboratories generally resolve these issues through risk assessment, method lifecycle management, and documented scientific justification.
In quality control laboratories, HPLC testing supports batch release, raw material checks, stability studies, and impurity profiling. A validated method defines sample preparation, instrument settings, calibration, and acceptance criteria. Analysts compare results with specifications and investigate out-of-specification outcomes before a batch is approved. Documentation includes chromatograms, integration records, audit trails, and reagent details. Because results influence product decisions, laboratories follow formal quality systems and data integrity rules. The exact tests and limits depend on the material, its intended use, and the applicable regulatory framework.
Detection commonly uses ultraviolet-visible absorbance, fluorescence, refractive index, or mass spectrometry. Ultraviolet detection depends on molecular chromophores that absorb light at specific wavelengths. Mass spectrometry provides mass information and sensitive quantification, often after electrospray ionization. Before sample batches, performance checks examine resolution, elution time repeatability, peak symmetry, and plate count. Matrix effects and co-elution remain recognized uncertainties; formal validation studies and orthogonal detection help address them. Detector choice depends on analyte properties and required sensitivity.
High-performance liquid chromatography, or HPLC, separates dissolved compounds by passing a liquid mobile phase through a packed column. Components distribute differently between the stationary phase and the moving liquid, so they travel at different speeds and exit at different times. A detector records these eluting bands as peaks, and peak area or height relates to amount. The technique supports testing in pharmaceuticals, foods, environmental samples, and industrial chemicals. Quantification usually depends on calibration with known standards.
| Property | Value | Notes |
|---|---|---|
| Primary guidance | ICH Q2(R2) | Analytical procedure validation |
| Compendial chapter | USP <621> | Chromatography general chapter |
| Validation parameter | Accuracy | Closeness to accepted true value |
| System suitability check | Peak resolution | Ensures separation between adjacent peaks |
| Data record | Audit trail | Supports data integrity and traceability |
Separation in HPLC depends on the chemistry of the stationary phase, the composition of the mobile phase, and the physical properties of the column. Reverse-phase separations use a nonpolar stationary phase and a polar mobile phase, and they are common for many organic compounds. Ion-exchange, size-exclusion, and normal-phase modes serve other classes of analytes. Gradient elution changes solvent strength over time, while isocratic elution holds it constant. Flow rate, temperature, particle size, and column length all influence peak shape and resolution. Detection may use ultraviolet absorbance, fluorescence, refractive index, or mass spectrometry, depending on the analyte and the required sensitivity.
Routine HPLC testing compares a sample result with a calibration curve prepared from known reference standards. Peak area or peak height is plotted against concentration, and the curve is used to estimate unknown amounts. Retention time supports tentative identification when compared with a standard, though mass spectrometry or another confirmatory method may be needed for definitive identification. Pre-run checks verify repeatability, resolution, and peak symmetry before sample analysis. Limits of detection and quantification describe the smallest amounts that can be reliably observed or measured. Sample preparation, filtration, and degassing help prevent column damage and inconsistent results.
Method validation demonstrates that an HPLC procedure is suitable for its intended purpose. Common validation parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantification, and robustness. Accuracy reflects agreement with a reference value, while precision describes repeatability under defined conditions. Specificity shows whether the method can measure the analyte in the presence of impurities or matrix components. Validation documents are reviewed before a method is used for routine testing or regulatory submissions.
System suitability testing is performed before and during analytical runs to confirm that the instrument and method are working as expected. Typical checks include retention time, peak area precision, resolution between critical pairs, tailing factor, and theoretical plate count. Acceptance criteria are set in the method or pharmacopeial monograph. If a suitability check fails, the run may be rejected and the instrument or sample preparation may need investigation. This practice helps prevent release of data from a system that has drifted out of control.
Method validation establishes that an HPLC procedure is suitable for its intended use. Key parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Accuracy measures agreement with a true or accepted value, while precision describes repeatability and intermediate precision. Specificity confirms that the method measures the analyte without interference from impurities, degradants, or excipients. Validation is documented in a protocol and report, and acceptance criteria are set before experiments begin. Regulatory guidance varies by region, but the general principles are widely harmonized.
System suitability testing is performed before and during analytical runs to confirm that the instrument and method are working as expected. Common checks include retention time, peak area, resolution between critical pairs, tailing factor, and theoretical plate count. Results are compared with predefined limits, and a failed check requires investigation before sample results are reported. Quality control samples at low, middle, and high concentrations are injected at intervals to monitor accuracy and precision. Blank injections detect carryover and contamination, while control charts track performance over time.
Data handling and documentation are central to HPLC quality control. Electronic systems should have audit trails that record changes to methods, sequences, and results. Integration parameters, such as peak baseline and threshold, can affect reported areas and must be defined in advance. Out-of-specification results trigger a structured investigation that may include reanalysis, instrument checks, and review of sample preparation. Regulatory inspections often examine raw data, audit trails, and training records to verify that reported results are traceable and reliable.
High-performance liquid chromatography is an analytical technique that separates components in a liquid sample by passing them through a packed column under pressure. A pump delivers a mobile phase at a controlled flow rate, and an injector introduces the sample into the stream. Differences in how analytes partition between the mobile phase and the stationary phase cause them to exit the column at different times. Detection then records a signal proportional to the amount of each separated substance. The resulting chromatogram provides retention times and peak areas for identification and quantification.
Instrumentation includes a solvent delivery system, an autosampler, a column oven, and one or more detectors. Reversed-phase columns with chemically modified silica are widely used, but normal-phase, ion-exchange, size-exclusion, and affinity modes exist for specific separations. Detectors may rely on ultraviolet absorbance, fluorescence, refractive index, or mass spectrometry. Column temperature, mobile phase composition, and flow rate are adjusted to improve resolution. System pressure is monitored because rising pressure can indicate column blockage or deteriorating packing.
=== Genetics === Two-thirds of families with a history of type 2 diabetes report more than one family member having MASLD. There is a higher risk of fibrosis for family members where someone was diagnosed with MASH. Asian populations are more susceptible to metabolic syndrome and MASLD than their Western counterparts. Hispanic persons have a higher prevalence of MASLD than white individuals, whereas the lowest prevalence is observed in black individuals. MASLD is twice as prevalent in men as in women, which might be explained by lower levels of estrogen in men. Genetic variations in two genes are associated with MASLD: non-synonymous single-nucleotide polymorphisms (SNPs) in PNPLA3 and TM6SF2. Both correlate with MASLD presence and severity, but their roles for diagnosis remain unclear. Although MASLD has a genetic component, the American Association for the Study of Liver Diseases (AASLD) does not recommend screening family members as there is not enough confirmation of heritability, although there is some evidence from familial aggregation and twin studies.
=== Additional toxic effects === Apart from its mutagenic nature, thiotepa can exert skin toxicity, such as redness and hyperpigmentation. Other less frequent symptoms are peeling skin and mucositis. These effects can be unified under the term of "toxic erythema of chemotherapy". Due to thiotepa's excretion via sweat, skin exposure is especially high in regions with a high density of sweat glands. Namely, symptoms are more abundant at skin folds, the groin, armpits, and generally obstructed skin where accumulation of sweat can take place. The symptoms can be minimized by washing the skin with water and preventing the use of soap and moisturizers, together with preventing obstructions of the skin, 36 hours after thiotepa administration. Thiotepa's ability to cross the blood-brain barrier can lead to diseases related to the white brain matter and neurotoxic symptoms such as memory deficits, dizziness, blurred vision, and others. Additionally, neurotoxicity and mucositis are the main dose-limiting factors in high-dose treatment (whereas the main dose-limiting factor, myelosuppression, is remedied by applying transplantation of bone marrow). Other general adverse effects of chemotherapy with thiotepa are infections, diarrhea, nausea, vomiting, oedema and hair loss. In-vivo experiments in animals displayed additional and potentially important toxicities. Thiotepa has been found to negatively affect fertility in male and female mice by interfering with spermatogenesis and impairing ovarian function, respectively.
=== Development and rationale === The TOPS System was developed in the early 2000s, with the concept of facet joint replacement introduced by biomedical engineer Uri Arnin. The idea was based on clinical observations that many patients undergoing lumbar spinal fusion have preserved intervertebral discs with degenerative spine pathology affecting the posterior elements of the vertebrae, including spinal stenosis, spondylolisthesis, and facet arthrosis. This led to the development of a motion-preserving alternative to fusion designed to maintain spinal stability following decompression. The first clinical implantations were performed in 2005, followed by international clinical use and subsequent randomized controlled trials comparing the device with fusion.
Directing edits to correct mutated sequences was first proposed and demonstrated in 1995. This initial work used synthetic RNA antisense oligonucleotides complementary to a pre-mature stop codon mutation in a dystrophin sequence to activate A-to-I editing of the stop codon to a read through codon in a model xenopus cell system. While this also led to nearby inadvertent A-to-I transitions, A to I (read as G) transitions can correct all three stop codons, but cannot create a stop codon. Therefore, the changes led >25% correction of the targeted stop codon with read through to a downstream luciferase reporter sequence. Follow on work by Rosenthal achieved editing of mutated mRNA sequence in mammalian cell culture by directing an oligonucleotide linked to a cytidine deaminase to correct a mutated cystic fibrosis sequence. More recently, CRISPR-Cas13 fused to deaminases has been employed to direct mRNA editing. In 2022, therapeutic RNA editing for Cas7-11 was reported. It enables sufficiently targeted cuts and an early version of it was used for in vitro editing in 2021.
The significance of these additional actions for Auvelity's antidepressant effects remains unclear. The combined pharmacological actions of DXM and bupropion make Auvelity function similarly to an SNDRI (serotonin-norepinephrine-dopamine reuptake inhibitor), simultaneously enhancing all three monoamine neurotransmitter systems. This characteristic may contribute to its relatively rapid antidepressant onset. The role of NMDA antagonism in Auvelity appears to be relatively limited. Ketamine and related compounds do indeed owe their rapid antidepressant effects to NMDA receptor antagonism. However, subsequent studies of numerous NMDA antagonists have found that most do not exhibit antidepressant efficacy. The reason appears to be that antidepressant activity requires exceptionally stringent molecular properties for NMDA receptor antagonism, particularly highly specific receptor-binding kinetics. In practice, neither DXM nor dextrorphan fulfills these requirements. This likely explains why Auvelity requires approximately 8 days to produce antidepressant effects, whereas esketamine can begin working within only a few hours. Therefore, although Auvelity substantially shortens the onset of action compared with conventional oral antidepressants, its mechanism underlying the accelerated antidepressant response appears to have only a limited relationship to the rapid antidepressant mechanism of ketamine.
Sources: en.wikipedia.org
=== Jewelry === In August 2025, within the course of a joint project with the European Commission monitoring online marketplaces such as Temu, AliExpress and Shein, the Latvian Consumer Rights Protection Centre, while testing a selection of best-selling jewelry goods, discovered extreme quantities of cadmium in 60% of the tested products. Some of the items were found to consist mostly of cadmium, at a purity of 80% or higher, in one case — a ring from AliExpress shaped like a snake — an impressive 92% cadmium alloy, evidencing that there is at least one jewelry manufacturer that has been using cadmium at some point as the primary material for its products and may still be doing so.
== Production == The dish gained popularity during the rationing in World War II, but declined over the following decades. The "nose-to-tail eating" trend has resulted in greater demand for faggots in the 21st century; British supermarket chain Waitrose once again sold beef faggots from 2014. In 2018, it was estimated that "tens of millions" of faggots were eaten every year.
=== Gene / location === The ERAP1 gene (HGNC: 18173) is located at the long arm of chromosome 5 (5q15). The gene is ~47Kb in length and contains 20 exons and 19 introns, which encode 9 different splice variants. The coding sequence shows a high degree of conservation among placental mammals (>80% identity). The sequences of 227 ERAP1 orthologs identified in approximately 200 species are available.
Chlorothalonil (2,4,5,6-tetrachloroisophthalonitrile) is an organic compound mainly used as a broad spectrum, nonsystemic fungicide, with other uses as a wood protectant, pesticide, acaricide, and to control mold, mildew, bacteria, algae. Chlorothalonil-containing products are sold under the names Bravo, Echo, and Daconil. It was first registered for use in the US in 1966. In 1997, it was the third most used fungicide in the US, behind only sulfur and copper, with 12 million pounds (5.4 million kilograms) used in agriculture that year. Including nonagricultural uses, the United States Environmental Protection Agency (EPA) estimates, on average, almost 15 million lb (6.8 million kg) were used annually from 1990 to 1996.
Sources: en.wikipedia.org
=== PCR method === PCR-based screening methodologies are in the process of development for a number of genes responsible for resistance. They speed up detection and can readily differentiate between carbapenamase genes-sometimes in a multiplex format. Costs of PCR testing are decreasing and reliability of molecular based tests relates more to gene presence and gene expression for production of the relevant carbapenamase. Nested arbitrary PCR (ARB-PCR) was used during a 2007 CRE outbreak at the University of Virginia Medical Center to identify the specific bla KPC plasmid involved in the transmission of the infection, and researchers suggest that ARB-PCR may also be used to identify other methods of CRE spread.
This is important because polysaccharide vaccines elicit antibody responses without T cell help, and as a result, those antibody responses tend to be weak and short-lived (and young children have a particularly difficult time generating these antibodies for developmental reasons, which is a major issue because the polysaccharides in question are present on the surfaces of pathogenic bacteria). However, attaching the polysaccharide to a carrier protein (especially an immunogenic one, such as tetanus toxoid) enables B cells that recognize the polysaccharide to get help from T cells that recognize the carrier protein's peptides. These are known as conjugate vaccines or glycoconjugates. Moreover, the processing of an antigen by an antigen-presenting cell causes loss of the tertiary structure of the protein, meaning that T cells recognize linear epitopes only (the amino acids recognized have to be next to each other in the primary structure). There are also subsets of T cells known as unconventional T cells that may recognize non-peptide antigens, or peptides. Many of these subsets show predominantly innate, rather than adaptive, functions.
Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin. Risk factors for developing breast cancer include obesity, a lack of physical exercise, alcohol consumption, hormone replacement therapy during menopause, ionizing radiation, an early age at first menstruation, having children late in life (or not at all), older age, having a prior history of breast cancer, and a family history of breast cancer. About five to ten percent of cases are the result of an inherited genetic predisposition, including BRCA mutations among others. Breast cancer most commonly develops in cells from the lining of milk ducts and the lobules that supply these ducts with milk. Cancers developing from the ducts are known as ductal carcinomas, while those developing from lobules are known as lobular carcinomas. There are more than 18 other sub-types of breast cancer. Some, such as ductal carcinoma in situ, develop from pre-invasive lesions. The diagnosis of breast cancer is confirmed by taking a biopsy of the concerning tissue. Once the diagnosis is made, further tests are carried out to determine if the cancer has spread beyond the breast and which treatments are most likely to be effective.
Sources: en.wikipedia.org
System suitability is a set of checks performed before and during an HPLC run to confirm that the instrument and method are working as expected. It may include retention time repeatability, resolution between peaks, peak symmetry, and signal intensity. Failing suitability criteria usually invalidates the run.
An HPLC method is typically validated before its routine use and revalidated in part when significant changes affect the method. Regulators do not set a universal calendar interval. The need for revalidation depends on the change, its risk, and the applicable guidance.
Validation establishes that a method is suitable for its intended purpose, often through a planned study. Verification confirms that a laboratory can reproduce a previously validated or compendial method under its own conditions. Verification is usually narrower than full validation.
HPLC separates and quantifies compounds in a liquid sample. Detectors produce a response proportional to the amount of a compound passing through the flow cell. Identification by retention time requires comparison with a known standard.